Abstract The management of chronic myelogenous leukemia
Abstract The management of chronic myelogenous leukemia (CML) has become complex due to the availability of improved diagnostic procedures and life-prolonging or even curative treatment strategies that are more successful the earlier they are applied in the course of the disease. This is true for allogeneic bone-marrow transplantation, treatment with interferon a (IFN) and Philadelphia-negative stem-cell collections for autografting. Outcome differs according to risk profiles of patients at diagnosis. In addition, molecular techniques for the detection of the BCR-ABL fusion gene or its products, such as the reversetranscriptase polymerase chain reaction (PCR), Southern blot analysis, or fluorescence in situ hybridization, facilitate accurate diagnosis and the monitoring of residual disease. They allow the individualization of treatment such as early infusion of donor lymphocytes if molecular relapse is detected after allografting, or discontinuation of IFN in the presence of very low BCR-ABL transcript levels). The availability of realtime PCR devices further improves and accelerates the diagnosis and monitoring of residual disease. This article addresses recent developments in drug therapy and allografting, including treatment intensification with low-dose ara C or intensive chemotherapy followed by autografting, introduction of new drugs (such as homoharringtonine or tyrosine kinase inhibitor STI571), progress with unrelated donor transplantations, use of peripheral blood stem cells for allografting, and transplantation without myeloablative conditioning. Tradeoffs between the treatment options will be discussed in the context of the evidence-based guidelines for treating CML, as recently published by the American Society of Hematology. Finally, the new competence network on acute and chronic leukemias will be introduced.
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Intensification of interferon-based therapies
It is now generally accepted that interferon a (IFN) and, to a lesser extent, hydroxyurea (HU), prolong survival in chronic myelogenous leukemia (CML) patients (Fig. 1) . Four randomized studies [2±5] and a meta-analysis [6] have shown that IFN prolongs survival by approximately 20 months compared with busulfan in the German study and HU in other studies (Table 1 and Table 2 ), depending on the risk profile at diagnosis [2±5, 7±10]. Differences among the four studies are mainly due to variations in patient risk profiles. If patient populations are adjusted to uniform prognostic criteria, survival curves are almost identical, as shown in a comparison of the German and Italian randomized studies [11] . Evolving evidence suggests that outcome is better if treatment is started early (within 6 months of diagnosis) and in patients R. Hehlmann´A. Hochhaus´U. Berger´A. Reiter III. Medizinische Klinik, Universitätsklinikum Mannheim, Universität Heidelberg, Wiesbadener Str. 7-11, D-68305 Mannheim, Germany Fig. 1 Interferon-a versus hydroxyurea versus busulfan. German chronic myelogenous leukemia study I, update June 1998. The differences between hydroxyurea and IFN versus busulfan are significant with less than 10 % blasts in the peripheral blood and no other signs of acceleration. Since survival outcome is dependent on the risk profile at diagnosis, the establishment of reliable prognosis scores was important. The generally accepted score of Sokal [12] was recently improved and adapted to IFN treatment (http://www.pharmacoepi.de [13] ). The scores are shown in Tables 2 and 3. There is evidence for a dose±response relationship of IFN treatment [14] . In most studies that show that IFN improves survival, it is combined with other agents, mostly HU. The single trial in which IFN was used as a monotherapy did not show a survival benefit compared with the use of HU [2] . Although prolongation of survival is the most important benefit of IFN therapy, available evidence suggests that prolonged survival is primarily achieved when IFN treatment is started during the early chronic phase and complete hematological and major cytogenetic remission [less than 35 % Philadelphia chromosome (Ph)-positivity] are induced. Complete hematological remission is accomplished after a median of 6 months [2] ; complete cytogenetic remission (0 % Ph-positivity) occurs after a median of 12±17 months [15] . Intensification of treatment by the addition of low doses of ara-C further increases cytogenetic remission rate and survival, as shown by two recent randomized studies [9, 16] .
Several lines of evidence suggest that survival in CML patients correlates with tumor burden [9, 16±27] . This evidence emerged from early studies using intensive chemotherapy, which demonstrated cytogenetic remission rates up to 70 % [28] and from survival analyses of 148 patients who relapsed after allogeneic marrow transplantations and had a significant survival advantage over 470 matched controls with conventional therapy (P = 0.0002). The evidence also comes from the above-mentioned observation that prolongation of survival by IFN is more evident and more pronounced if HU and low doses of ara-C are added. Several ongoing studies apply this concept by either adding moderate doses of ara-C and idarubicine to an induction treatment consisting of IFN and HU or using high-dose chemotherapy followed by autografting. Examples are studies III and IIIA of the German CML Study Group and the autografting study recently started by the European Group of Blood and Marrow Transplantation.
New drugs
Despite considerable progress, it is unlikely that IFNbased and/or intensified-treatment strategies will provide a cure. Therefore, the development of new drugs is of particular interest (Table 4) [29±33]. Two publications report on the use of the alkaloid homoharringtonine in early-[31] and late-phase CML [30] . Although beneficial effects on symptoms, survival, and cytogenetic remissions are reported, no clear advantage over IFN is recognizable. It remains to be seen whether a combination of IFN and homoharringtonine has any significant survival advantage.
A particularly interesting new drug is the rationally designed BCR-ABL tyrosine-kinase inhibitor STI571. In contrast to other inhibitors of tyrosine kinase, STI571 shows specificity for the BCR-ABL tyrosine 
Molecular diagnostics in long-term IFN treatment
A substantial minority of IFN-treated patients achieve complete cytogenetic remission, which corresponds to a prolongation of the chronic phase and of survival [35] . Quantitative monitoring of minimal residual disease is of major interest in these patients. Since patients with leukemia at presentation or relapse usually have a total burden of more than 10 12 malignant cells [36] , and since cytogenetics, Southern blotting, western blotting, and conventional fluorescence in situ hybridization have a sensitivity of no more than 1 %, a patient with negative results may harbor as few as zero or as many as 10 10 residual leukemic cells. At this point, the patient is judged to be in clinical and hematological remission, although the term "remission" refers only to an arbitrary point toward one end of leukemic cell number [37] .
Recent evidence from 54 patients in complete cytogenetic remission due to IFN treatment shows that all patients had molecular evidence of residual disease during complete remission (CR), although three patients were intermittently negative according to reverse-transcriptase polymerase chain reaction (RT-PCR). In general, BCR-ABL transcript numbers, as determined by quantitative competitive PCR [38], were inversely related to the duration of CR. The median ratio of BCR-ABL to ABL at the time of maximal response for each patient was 0.045 % (range 0±3.6 %). During the period of observation, 14 patients relapsed ± 11 cytogenetically to the chronicphase disease and three directly to the blastic phase. The median ratio of BCR-ABL/ABL at maximal response was significantly higher in patients who relapsed than in those who remained in CR (0.49 % versus 0.021 %, P < 0.0001) [39] . The findings demonstrate that the level of residual disease decreases with time in patients who maintain their cytogenetic response to IFN, but residual disease is rarely (if ever) eliminated. The RT-PCR analysis of CFU-GM colonies grown from bone marrow of eight complete cytogenetic responders demonstrated that residual disease resides in myeloid colony-forming cells, which may have the potential to repopulate the bone marrow and contribute to relapse [40] . Therefore, a molecular elimination of CML is unlikely by IFN therapy. The actual level of minimal residual disease correlates with the probability of relapse. For patients who reach complete cytogenetic remission, treatment should be continued at least until relatively low levels of residual leukemia are achieved.
Experience with some patients in continued complete cytogenetic remission has shown that remission may be maintained even after discontinuation of IFN [41] . It remains to be seen whether these are anecdotal observations in a few cases or observations relevant for a larger group of patients in the future. If prolonged survival is observed ± even in the presence of residual disease ± this would be relevant for the respective patients as an ªoperational cureº.
New real-time RT-PCR procedures promise to simplify the cumbersome protocols that are currently in use. They offer a unique opportunity to standardize the assay and to develop rigorous standards and controls [42] . Quantitative real-time PCR will shortly become a routine and robust basis for clinical decision making, both in CML and in other hematological malignancies with specific molecular markers.
Using an ªoptimizedº RT-PCR method, BCR-ABL messenger RNA can be detected at a very low level and with an age-dependent frequency in normal individuals ( Fig. 2) [43, 44] . One interpretation of this finding could be that BCR-ABL, and probably several other fusion genes, are continuously formed in mitotic cells in the normal bone marrow, but only the combination of the correct BCR-ABL fusion in the correct 
Allogeneic transplantation
Despite the progress in drug treatment, allografting remains, at present, the only potentially curative treatment option for CML [46] . Problems are the requirement of a stem cell donor and the degree of physical fitness, excluding older patients and those with other relevant illnesses. In addition, the early procedure-related mortality and morbidity limit the general use of this procedure. Five-year survival after allografting ranges between 40 % and 80 % (Table 5) [47±52]; the better results are accomplished by more experienced centers [1] . In most series, the 5-year survival after transplantation in chronic phase ranges between 50 % and 60 % [52] . In order to better quantify the transplantation risk, a score for risk assessment was generated [53] . The score uses the major pre-transplant risk factors: histocompatibility, the stage of disease at time of transplantation, the ages and genders of donor and recipient, the time from diagnosis to transplantation, and the year of transplantation. The score categorizes patients into eight risk levels: level 0 represents the lowest risk, and level 7 the highest risk.
Results from transplantation with unrelated donors in recent series do not appear to be inferior to transplantations with related donors [54, 55] . The availability of peripheral stem cells instead of bone marrow will facilitate the transplantation procedure [56±58], and one report indicates that the risk of relapse might be reduced if peripheral blood stem cells are used [59] . Since this observation is not shared by others [60] , a randomized study is underway to address this question [56] .
As many as one-third of patients, however, die from complications soon after the procedure, a situation that creates dilemmas for patients and their doctors in deciding about treatment, particularly considering the favorable long-term survival results in some IFN-treated patients [13, 16] . Although the majority of patients ultimately decide to proceed with the transplantation despite the risk of procedure-related early death, the decision involves difficult tradeoffs. Is it better to choose treatment with IFN and have a good quality of life, even if it is of limited duration, or to take the chance of a cure with the considerable risk of early death due to the transplantation procedure? There is no easy answer, and the personal preferences of patients have to be considered. In many instances, it probably is best to present the available evidence to the patients and, if possible, to share in the treatment decision [1] .
Allogeneic bone-marrow transplantation versus IFN treatment
In order to quantify tradeoffs between the best available drug treatment and allogeneic bone-marrow transplantation (BMT), a randomized prospective study is desirable. Since the results of one ongoing study will not be available for several years, a retrospective comparison of the survival of patients treated with IFN and HU with the survival of a cohort that received human leukocyte antigen (HLA)-matched transplants from related donors was performed to quantify the risks and benefits of both procedures [52] . In addition to the interval between diagnosis and High-risk patients and patients who underwent transplantation early benefited most from the procedure and had a significant survival advantage after 4±4.8 years. However, most low-risk patients and patients who underwent transplantation late, although to a lesser extent, were likely to benefit, with a significant survival advantage after 6.5 years to more than 7.8 years. This analysis led to the conclusion that BMT should be recommended for most patients with CML who can tolerate the procedure. Until recently, the possibility of curing CML was realistic only for a minority of young patients. The availability of unrelated donors (thanks to more than six million volunteers enrolled in bone-marrow donor registries worldwide) now offers potentially curative BMT as a realistic option for the majority of CML patients who are young enough and can tolerate the procedure [54] . Fig. 4 . Approximately two-thirds of complete responders after allogeneic BMT are RT-PCR negative within 1 year, but almost all IFN-responders harbor residual BCR-ABL transcripts.
Drug treatment before allogeneic BMT
Despite these favorable prospects, early BMT-associated mortality would favor a trial with IFN first in most patients, and transplantation only if the response to IFN is unsatisfactory. Delay of transplantation, however, might lower the probability of cure, because the success rate of transplantation decreases as the time elapsed after the diagnosis of CML increases [47] . Still, a limited trial with IFN of 6±12 months duration could be discussed. This concept is challenged by three reports [51, 63, 64] , which suggest that, in addition to the time aspect, IFN itself may be harmful for a subsequent transplantation because of increased transplantation-related early-death rates due to graft rejection or graft-versus-host disease (GvHD). A prospective analysis of 152 patients transplanted during the chronic phase in two randomized studies comparing IFN (with or without chemotherapy) with chemotherapy alone showed that the outcome after BMT is not compromised by pre-treatment with IFN if it is discontinued at least 3 months prior to transplantation (Fig. 5) . The 5-year survival was 46 % for the 50 patients who received IFN until BMT and was 71 % for the 36 patients who discontinued IFN at least 3 months prior to BMT (P = 0.0057) [55] . This finding was similar for recipients of related and non-related transplants.
Relapse after allogeneic BMT
In a minority of cases, relapse of CML is observed after allogeneic BMT. Monitoring by quantitative PCR for BCR-ABL transcripts allows one to predict relapse early (molecular relapse [65] ). Successful treatment of relapse can be achieved, e.g., by the infusion of donor lymphocytes [66] and by IFN treatment [67] . The observation that donor lymphocytes can induce CR after relapse of CML [66, 68] has led to the concept that immune surveillance and the graft-versusleukemia (GvL) effect may be more important for disease control in CML than intensive chemotherapy. Indeed, recent advances in allografting with non-myeloablative conditioning approaches support this concept [69, 70] . Since much of the transplantation-associated morbidity and mortality is ascribed to the effect of the intensive chemotherapy, patients not eligible for standard allografting might be offered a potentially curative transplantation approach. GvHD, however, will probably remain a problem. This non-myeloablative transplantation or ªmini-transplantº approach is another field that will require close attention in the near future.
Autologous stem-cell transplantation
Increasing evidence has shown that non-clonal Ph-negative hematopoietic progenitors co-exist with the Phpositive leukemic clones in the bone marrow of CML patients at diagnosis. High numbers of the Ph-negative hematopoietic progenitors can be mobilized by intensive chemotherapy, particularly during the early chronic phase [71] . These cells are subsequently used to re-establish Ph-negative hematopoiesis after highdose chemotherapy, which is thought to reduce tumor burden such that the emergence of a blast-phase subclone is delayed. It has been shown that autografting can result in prolonged restoration of Ph-negative hematopoiesis and may, therefore, increase survival significantly, at least in some patients [72] . The major drawback of autografting is the re-infusion of leukemic cells and the lack of a GvL effect which might be overcome in the future by new in vitro and in vivo purging techniques and new insights for the targeting of the immune system.
Evidence-based guidelines for treating CML
An international panel of hematologists and methodologists convened by the American Society of Hematology reviewed the strength of the evidence regarding the benefits and harms of chemotherapy and allografting in order to determine whether evidence-based treatment guidelines could be developed [1] . Based on evidence from randomized, controlled trials, they concluded that: 1. Patients with good prognostic factors in the early stage of chronic-phase CML should be offered IFN, perhaps with added chemotherapy (HU or ara-C) to achieve the highest probability of survival. 2. Clinical trials that produced improved survival used the maximally tolerated dose (white blood cells = 2000±4000 ml
±1
; platelets>50,000 ml
; no signs of toxicity). 3. There is inadequate evidence from controlled trials to recommend an optimal duration of IFN therapy. 4. Prolonged survival is most likely when a major or complete cytogenetic response is obtained after IFN therapy. 5. There is inadequate evidence to set an upper age limit for considering IFN therapy for CML. 6. Based on proven effects on survival, there is inadequate evidence (from controlled trials) to recommend IFN over chemotherapy for patients in the advanced chronic phase. 7. For those patients who prefer conventional chemotherapy rather than IFN, evidence supports the use of HU rather than busulfan as the agent more likely to improve survival and less likely to produce serious toxicity. German CML studies I and II, prospective analysis [55] Concerning allogeneic BMT, the guidelines state that: 1. If physicians and patients require evidence of benefit from BMT from randomized controlled studies to determine treatment preferences, then evidence to make such a recommendation is lacking. 2. Allogeneic BMT is an option if the patient has a suitable HLA-matched donor and an acceptable health status to tolerate the procedure. 3. Based on the information provided, a patient must fully understand the tradeoff between potential long-term benefits and the more immediate risk of transplant-related complications and mortality. 4. Allogeneic BMT should preferably be offered to patients within 1±2 years of diagnosis to achieve the greatest likelihood of success. 5. Younger patients are most likely to benefit from allogeneic BMT. 6. There is observational evidence that prior treatment with IFN does not compromise the results of matched, related transplants.
Treatment algorithm 2000
The guidelines recommend the following logical sequence of decisions in the management of CML: 1. The first consideration is to determine whether BMT is a viable option and begins with an orderly assessment of the patient's age and health status and the availability of a marrow donor (either match-related or non-related). 2. If a non-transplant regimen is selected, decisions regarding the details of drug administration are required. For example, if IFN is administered, its dose, duration and its combination with HU or ara C must be decided. 3. A systematic plan must be established for evaluating the degree and duration of cytogenetic and molecular remission. 4. Once the available treatment and diagnostic options are clarified, the tradeoffs, which involve both the potential outcomes of treatment and the patient's preferences and personal priorities, must be examined. Although there is no generally valid treatment algorithm, and many of the treatment decisions will be tradeoffs between the harms and benefits of treatment options in each individual case, the authors would like to conclude this review with a treatment algorithm that underlies the current treatment studies of the German CML Study Group (Fig. 6 ). This algorithm is continuously evolving on the basis of new evidence from clinical observations and therapy studies and provides an overview over the most important current treatment options, including some experimental procedures offered within ongoing study protocols.
Competence network on leukemia
Physicians interested in more rapidly obtaining information on current treatment options and new therapeutic developments in CML on the basis of therapy studies and new experimental approaches are invited to use the new competence network on acute and chronic leukemias that was recently established by the German Bundesminister für Bildung und Forschung for the promotion of research and patient care by means of improved cooperation. It can be consulted at the Internet site http://leukaemie.krebsinfo.de. 
